SPY447.17-0.71 -0.16%
DIA348.18-0.64 -0.18%
IXIC15,181.92+20.40 0.13%

BRIEF-Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases

reuters.com · 09/01/2021 07:29
BRIEF-Brickell Biotech Acquires Exclusive Rights To Phase 1-Ready Dyrk1a Inhibitor Program And Novel Platform Targeting Autoimmune And Inflammatory Diseases

- Brickell Biotech Inc BBI:

  • BRICKELL BIOTECH ACQUIRES EXCLUSIVE RIGHTS TO PHASE 1-READY DYRK1A INHIBITOR PROGRAM AND NOVEL PLATFORM TARGETING AUTOIMMUNE AND INFLAMMATORY DISEASES

  • BRICKELL BIOTECH INC - ACQUISITION INCLUDES RIGHTS TO PLATFORM OF DYRK1A INHIBITORS

  • BRICKELL BIOTECH INC - BRICKELL WILL MAKE A ONE-TIME PAYMENT TO VORONOI OF $2.5 MILLION IN CASH AND $2.5 MILLION IN SHARES OF BRICKELL COMMON STOCK

  • BRICKELL BIOTECH INC - NUMBER OF SHARES TO BE ISSUED TO VORONOI IS BASED ON A PRICE OF $0.89 PER SHARE

Source text for Eikon: ID:nGNXcgT0Sf

Further company coverage: BBI


((Reuters.Briefs@thomsonreuters.com;))